Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
18706 North Creek Parkway, Suite 104, Bothell, Washington
Fiscal year end
December 31
Former names
M3 Biotechnology, Inc. (to 1/23/2019)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 625 % -56.6%
Debt-to-equity 19 % +177%
Return On Equity -80.6 % -94.5%
Return On Assets -67.7 % -74.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3 M shares +1.01%
Common Stock, Shares, Outstanding 38.3 M shares +0.99%
Entity Public Float 96.3 M USD -2.73%
Common Stock, Value, Issued 4 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 38.3 M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 38.3 M shares +1.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 93.7 M USD +37.2%
General and Administrative Expense 31.3 M USD -2.57%
Costs and Expenses 123 M USD +11.8%
Operating Income (Loss) -123 M USD -11.8%
Nonoperating Income (Expense) 1.75 M USD +468%
Net Income (Loss) Attributable to Parent -116 M USD -13.4%
Earnings Per Share, Basic -3.05 USD/shares -13%
Earnings Per Share, Diluted -3.05 USD/shares -13%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.8 M USD -26%
Assets, Current 129 M USD -33.3%
Property, Plant and Equipment, Net 3.14 M USD -22.5%
Operating Lease, Right-of-Use Asset 992 K USD -18.2%
Other Assets, Noncurrent 55 K USD -23.6%
Assets 133 M USD -42.7%
Accounts Payable, Current 681 K USD -23.7%
Employee-related Liabilities, Current 2 M USD +0.96%
Accrued Liabilities, Current 14.5 M USD +63%
Liabilities, Current 25.6 M USD +27%
Operating Lease, Liability, Noncurrent 1.12 M USD -25.3%
Liabilities 26.7 M USD +23.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -137 K USD +86.7%
Retained Earnings (Accumulated Deficit) -336 M USD -53%
Stockholders' Equity Attributable to Parent 107 M USD -49.4%
Liabilities and Equity 133 M USD -42.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8 M USD +1.49%
Net Cash Provided by (Used in) Financing Activities 99 K USD -52.9%
Net Cash Provided by (Used in) Investing Activities 13 M USD -63.3%
Common Stock, Shares Authorized 900 M shares 0%
Common Stock, Shares, Issued 38.3 M shares +0.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.8 M USD -235%
Deferred Tax Assets, Valuation Allowance 71.2 M USD +65.7%
Deferred Tax Assets, Gross 71.8 M USD +63%
Operating Lease, Liability 1.5 M USD -18.3%
Depreciation 975 K USD +5.18%
Payments to Acquire Property, Plant, and Equipment 5 K USD -97.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -115 M USD -13%
Lessee, Operating Lease, Liability, to be Paid 1.71 M USD -21.5%
Property, Plant and Equipment, Gross 5.71 M USD +0.88%
Operating Lease, Liability, Current 380 K USD +12.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 509 K USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 494 K USD +2.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 213 K USD -38.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509 K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 31.3 M USD +30.1%
Unrecognized Tax Benefits 3.11 M USD +121%
Deferred Tax Assets, Net of Valuation Allowance 25.2 M USD +136%
Share-based Payment Arrangement, Expense 10.5 M USD -1.29%
Interest Expense 2 K USD